Luminex this week announced that the appointment of J. Stark Thompson to the board of directors, where he will serve as a class III director. Most recently, Thompson served as president, CEO and Director of Life Technologies. Thompson has a BS from Muskingum College and a MS and PhD in Physiological Chemistry from Ohio State University. He currently serves as chair of the board of directors of Gene Logic, as well as serving as a director in various other private and civic organizations.
Tom Daniel and Mark Carthy will not stand for re-election to the board of directors of Solexa at the company's June 7 annual stockholders' meeting, the company said last week. The two directors "informed the board" of their decisions on June 3, the company said. Both were appointed to the company's board in March.
Daniel is currently a general partner at Schroder Ventures Life Sciences and serves on the board of Third Wave Technologies.
Carthy serves as a director of Astex Technology, ImpactRx, Scion Pharmaceuticals, and Cyberkinetics, and he is a venture partner at Oxford Bioscience Partners.
ArQule last week appointed Ronald Lindsay to its board of directors, the company said. Lindsay currently "operates" Milestone Consulting, a biotechnology consulting enterprise, and is a director of Sequenom and Neuro3D, a privately held French company. Lindsay is also a member of the scientific advisory boards of Serono International and Rinat, and he serves as a senior advisor to TVM, a German/US venture capital group.